Trogocytosis (immunological synapse”.
- Steps in the discovery of trogocytosis 1
- Cell types performing trogocytosis 2
- Mechanisms of trogocytosis 3
- Physiological consequences of trogocytosis 4
- Implications of trogocytosis in serotherapeutic approaches 5
- Trogocytosis-based assays as immunomonitoring tools 6
- See also 7
- References 8
Steps in the discovery of trogocytosis
First indication for the existence of this process dates back late 70s when several research groups reported on the presence of unexpected molecules such as Major Histocompatibility complex molecules (MHC) on T cells. The notion that membrane fragments, and not isolated molecules, could be captured by T cells on antigen-presenting cells was suggested by the capture of MHC molecules fused to the green fluorescent protein (GFP) in their intracellular portion. The demonstration that membrane fragments were involved in this transfer process came when fluorescent probes incorporated in the plasma membrane of the antigen-presenting cell as well as non-MHC molecules were found to be captured by T cells together with the antigen.
Cell types performing trogocytosis
Trogocytosis has been initially documented in T, B and NK cells both in vivo and in vitro. On T cells and B cells, trogocytosis is triggered when the T cell receptor (TCR) on T cells or B cell receptor (BCR) on B cells interacts with the antigen recognized on antigen-presenting cells. Like in lymphocytes, trogocytosis occurs with PMN (polymorphonuclear leukocytes, also known as granulocytes) and is associated with effective ADCC (Antibody dependent cell mediated cytotoxicity). It was shown that in order to initiate ADCC in vitro, PMN's have to adhere to their target cells and form tight junctions with antibody opsonized tumor cells. This cell clustering precedes mutual membrane lipid exchange between effector and target cell during ADCC and does not happen in the absence of opsonizing antibodies. Trogocytosis also occurs in monocytes, and dendritic cells. Outside the immune system, similar transfer of membrane fragments have been documented between sperm and oocytes, a process thought to contribute to gamete fusion.
Mechanisms of trogocytosis
Trogocytosis involves the transfer of plasma membrane fragments from the presenting cell to the lymphocyte. Trogocytosis is specifically triggered by antigen receptor signalling on T and B cells, by killer inhibitory and killer activatory receptor on NK cells and by various receptors on other cells including Fc receptor and scavenger class A receptor. It is likely that trogocytosis does not involve the capture of vesicles such as exosomes secreted by antigen-presenting cells. Rather, molecules could move from antigen-presenting cells to lymphocytes conveyed by membrane nanotubes or membrane fragments could be torn by T cells due to physical forces required for immunological synapse formation and deformation. Depending on the two cell types involved in conjugates, trogocytosis can be unidirectional or bidirectional. Proteins transferred by trogocytosis are many and mostly include proteins inserted in or closely associated to the plasma membrane (proteins spanning the lipid bilayer or inserted in the extracellular or intracellular leaflets). For instance, human lymphocytes were recently shown to acquire the inner-membrane protein H-Ras, a G-protein vital for common lymphocyte functions and a prominent participant in human cancer, from the cells they scan. The transfer was cell contact-dependent and occurred in the context of cell-conjugate formation. Moreover, the acquisition of oncogenic H-RasG12V by NK- and T lymphocytes had important biological functions in the adopting lymphocytes: the transferred H-RasG12V induced ERK phosphorylation, increased interferon-γ and tumor necrosis factor-α secretion, enhanced lymphocyte proliferation, and augmented NK-mediated target cell killing.
Physiological consequences of trogocytosis
Trogocytosis can have physiological consequences in two ways : either because "recipient" cells acquire and make use of molecules they do not usually express or because « donor » cells are stripped of molecules, which may alter their interaction with cellular partners. Acquired molecules, such as regulatory molecules with extracellular or intracellular components might alter the lymphocytes activity and direct several lymphocyte functions, such as migration to the adequate injured tissues. Such gained plasma membrane fragments could also contribute to the capacity to proliferate, because lipids are highly energetic claiming components to establish. Trogocytosis might have appeared first in very primitive organisms to feed off other cells. Most of the biological functions identified for trogocytosis have been reported for lymphocytes and dendritic cells. Major findings along these lines are:
- cytotoxic T lymphocytes having captured antigenic peptide-MHC complexes can be killed by CTL specific for this antigen (a process termed « fratricide »)
- helper T lymphocyte having captured antigenic peptide-MHC complexes are involved in a negative regulatory feed-back loop leading to their inactivation 
- dendritic cells stripped of antigenic peptide-MHC complexes by T cells through trogocytosis contribute to affinity maturation of T cell response by seleting high affinity T cell 
- down-modulation of costimulatory molecules on dendritic cells mediated by T cells leads to regulation of T cell response 
- transfer of antigen between dendritic cells by trogocytosis favours reactivation of memory T cells at the expenses of naive T cells 
- transfer of antigen between dendritic cells by trogocytosis contributes to allograft rejection 
Implications of trogocytosis in serotherapeutic approaches
Therapeutic antibodies can be used to treat cancer. An example is rituximab, a therapeutic antibody used to treat chronic lymphocytic leukemia, recognizes the CD20 molecule expressed by tumor cells and leads to their elimination. However, using too much of the antibody results in part from the removal of rituximab-CD20 complexes from the tumor cell surface by monocytes through trogocytosis. This effect leads to tumors cell escape by antigenic modulation. Reducing the dose of therapeutic antibodies to limit the extent of trogocytosis might improve their therapeutic efficacy.
Epratuzumab (a CD22 Mab) acts using trogocytosis to transfer CD22 and other B-cell proteins from B cells to effector cells.
Trogocytosis-based assays as immunomonitoring tools
TRAP assays (TRogocytosis Analysis Protocol) allow to identify, characterize and purify T and B cells recognizing their specific antigen based on their ability to extract molecules (in that case, fluorescent probes) from the plasma membrane of antigen-presenting cells. These assays require equipment such as a flow cytometer but are otherwise very cheap, easy to perform, fast (can be performed within 3 hours) and applicable to any population of T or B cells. TRAP assays have been successfully used to detect T cell responses against viral infections, cancer, auto-immune diseases and vaccines.
- E. Joly and D. Hudrisier in Nature Immunology volume 4 page 815 (2003)
- JF. Huang et al in Science volume 256 page 952 (1999)
- D. Patel et al in Journal of Immunology volume 163 page 5221 (1999)
- D. Hudrisier et al in Journal of Immunology volume 166 page 3645 (2001)
- Horner, Frank, Dechant, Repp, Glennie, Martin Herrmann & Stockmeyer 2007
- V. Barraud-Lange et al. in Faseb Journal volume 21 page 3446 (2007)
- J. Helft et al. in Blood volume 112 page 1249 (2008)
- RM. Kedl et al. in Nature Immunology volume 3 page 27 (2002)
- OS. Qureshi et al. in Science volume 332 page 600 (2011)
- L. Wakim and MJ. Bevan. in Nature volume 471 page 629 (2011)
- ME. Williams et al. in Journal of Immunology volume 173 page 4828 (2004)
- PV. Beum et al. in Journal of Immunology volume 176 page 2600 (2006)
- OB. Herrera et al. in Journal of Immunology volume 177 page 7435 (2006)
- S. Daubeuf et al in Nature Protocols volume 1 page 2536 (2007)
- C. Beadling and MK. Slifka in Nature Medicine volume 12 page 1208 (2006)
- A. Machlenkin et al in Cancer Research volume 68 page 2006 (2008)
- B. Babhoui et al. in Brain volume 133 page 1622 (2010)
- S. Daubeuf et al in Vaccine volume 27 page 5565 (2009)